Roche Pharmaceutical Development and Sales Overview

2022 outlook confirmed Group sales growth1 Core EPS growth¹ • Stable to low-single digit • Dividend outlook • 1 At Constant Exchange Rates (CER) Low- to mid-single digit Further increase dividend in Swiss francs Roche 15

View entire presentation